

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Christian Widmann *et al.*

International Application No.: PCT/IB2004/002165

International Filing Date: June 30, 2004

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: **RASGAP DERIVED PEPTIDE FOR
SELECTIVELY KILLING CANCER CELLS**

Examiner: Not Yet Assigned

STATEMENT UNDER 37 C.F.R. 1.825(a) and 1.825(b)

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The submission of the substitute Sequence Listing filed concurrently herewith does not include new matter. Sequence ID numbers 5 – 17 have been included to reflect all of the sequences described in the specification. Thus, Sequence ID numbers 5 – 17 do not include new matter.


The copy of the substitute Sequence Listing in computer readable form filed concurrently herewith is the same as the paper copy of the substitute Sequence Listing filed concurrently herewith.

In accordance with the requirements of PCT Rule and 37 CFR 1.821-1.825, the material on the diskette submitted in the enclosed PCT Application is identical in substance to the Sequence Listing appearing on attached pages 1 through 7. Furthermore, the computer readable form of the Sequence Listing contained on said diskette is understood to comply with the requirements of PCT Rule 5, PCT Rule 13 and the Administrative Instructions.

Applicant believes no fee is due with this statement. However, if a fee is due, please charge our Deposit Account No. 12-0080, under Order No. KZI-004US from which the undersigned is authorized to draw.

Dated: December 28, 2005

Respectfully submitted,

By 
Cristin E. Howley, Ph.D.
Registration No.: 55,281
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant